Skip to main content
SpringerLink
Log in

Biotechnology Funding

  • Chapter
The Biotech Business Handbook

  • 290 Accesses

Abstract

Starting and operating a biotechnology company is both very expensive and excep tionally risky. A number of factors are responsible, including the high level of education required of those who conduct origin—nal research, the need that risk taker sboth scientists and businessmen be highly motivated, the lofty expense of high quality chemicals and biological reagents, as well as of such laboratory equipment as centrifuges, nucleic acid sequencers and synthesizers, microscopes, biological safety hoods, photometers, and electrophoresis apparatus; the cost of meeting federal, state, and local environmental and employee safety guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Pertinent Reading

Articles

  • An update on the electronic grant application development.NIH Peer Review NotesDivision of Research Grants, NIH, Westwood Building, Bethesda, MD 20892, June, 1991, pp. 8–11.

    Google Scholar 

  • Application for Public Health Service Grant (Including Research Career Development Awards and Institutional National Research Service Awards).US Department of Health and Human Services, Grant application form PHS 398, OMB No. 0925–0001 (Rev. 10/88).

    Google Scholar 

  • Bennett, J.C. 1993. Inclusion of women in clinical trials—Policies for population subgroups (Special Report).N.E.J.M.329:288–292.

    Article  CAS  Google Scholar 

  • Brown, K.D. 1992. Financing biotech companies in the years ahead-Where will the dollars come from?GEN12(14):1.

    Google Scholar 

  • Byers, B.H. 1991. Relationship between venture capitalist and entrepreneur. in:Pratt’s Guide to Venture Capital Sources.Venture EconomicsInc., Needham, MA, pp. 85–87.

    Google Scholar 

  • Code of Federal Regulations, Title 56, Part 28004, sections 101(b) and 101(h), final common rule. Protection of human subjects. June 18,1991.

    Google Scholar 

  • Common rule for the protection of human subjects.NIH Peer Review NotesDivision of Research Grants, NIH, Westwood Building, Bethesda, MD 20892, October,1991, pp. 5–6.

    Google Scholar 

  • Diesenhouse, S. 1992. The northeast looks to biotech-nology for relief.New York TimesMarch 8, p. F12.

    Google Scholar 

  • Dolnick, E. 1983. Research on primates challenged.Boston GlobeApril 25, p. 35.

    Google Scholar 

  • DuCross, M. and A. Ferguson. 1993. Factors that will define VC investments in the bioindustry into the next century.GEN13(8):12.

    Google Scholar 

  • Eaves, G.N. 1973. The grant application: An exercise in scientific writing.Fed. Proc.32:1541–1543.

    PubMed  CAS  Google Scholar 

  • Gebhart, F.1990. Industry considers the Roche-Genentech deal a major vote of confidence for biotechnology.GEN10(3):1.

    Google Scholar 

  • Gebhart, F. 1992. Xerox/Q-Lifejoint venture product speeds up the gene mapping process.GEN12(3):26.

    Google Scholar 

  • Gibbons, A. 1991. Chiron buys Cetus: A tale of two companies.Science253:503–504.

    Article  PubMed  CAS  Google Scholar 

  • Gordon, S.L. 1989. Ingredients of a successful grant application to the National Institutes of Health.J. Orthopaed. Res.7:138–141.

    Article  CAS  Google Scholar 

  • Heidrich, A.G. 1994. Resetting the model for longterm success.Bio/Technology12(4):342–345.

    Article  Google Scholar 

  • Hemley, R. 1991. Chiron-Cetus combination creates powerful and diversified competitor in healthcare.GEN11:1.

    Google Scholar 

  • Henriques, D.B. 1991. Disguising the risks of research.New York TimesFebruary 31.

    Google Scholar 

  • Inclusion of women and minorities and women in study populations (NIH Manual 4000 & 6000). NIH Instruction and Information Memorandum OER 90–5, December 11, 1990.

    Google Scholar 

  • Lehrman, S. 1992. Cetus: A collision course with failure.The ScientistJanuary 20.

    Google Scholar 

  • Lewis, R. 1993. Biotech startups’ business and science missions must be crystal clear from day one, experts say.The ScientistApril 19, 7:1.

    Google Scholar 

  • Merritt, D.H. and G.N. Eaves. 1975. Site visits for the review of grant applications to the National Institutes of Health; Views of an applicant and a scientist administrator.Fed. Proc.34:131–136.

    PubMed  CAS  Google Scholar 

  • Morriss, J.K. 1991. An overview of the venture capital industry. in:Pratt’s Guide to Venture Capital Sources.Venture Economics Inc., Needham, MA, pp. 7–9.

    Google Scholar 

  • Murphy, D.G. and D.J. Dean. 1986. Application and review procedures for the NIH small business innovation research program.Institute InsightMarch, pp. 1–12.

    Google Scholar 

  • NIH Peer Review Notes.Division of Research Grants, NIH, Westwood Building, Bethesda, MD 20892.

    Google Scholar 

  • Nussbaum, B. 1991. Under-the-counter drug testing.New York TimesFebruary 19.

    Google Scholar 

  • Omnibus Solicitation of the Public Health Service for Small Business Innovation Research (SBIR) Grant Applications.Department of Health and Human Services, PHS 91–2.

    Google Scholar 

  • Pappas, M.G. 1990. How biotech firms can get research grants without giving up equity.Bus. Dig. Centr. Mass.9(9): 17–19.

    Google Scholar 

  • Pappas, M.G. 1991. How biotech firms can get research grants without giving up equity (Part 2).Bus. Dig. Centr. Mass.10(1):35–36.

    Google Scholar 

  • Pappas, M.G. 1992. How biotech firms can get research grants without giving up equity (Part 3).Bus. Dig. Centr. Mass.11(4):19–21.

    Google Scholar 

  • Percentiling.NIH Peer Review NotesDivision of Research Grants, NIH, Westwood Building, Bethesda, MD 20892, October, 1991, pp. 3–4.

    Google Scholar 

  • Pike, J.M. and S.C. Bernard. 1978. The research grant budget: Preparation and justification in relation to the proposed research.Grants Magazine1:283–286.

    PubMed  CAS  Google Scholar 

  • Pramik, M.J. 1990. NIH redrafts its guidelines to cover conflicts of interest. GEN 10(3):1.

    Google Scholar 

  • Sannes, L. 1991. While some companies try to part-ner, others decide to go it alone.GEN11:6–7.

    Google Scholar 

  • Schlossberg, K. 1991. Equal rights for women’s health.New York TimesApril 23, p. 30.

    Google Scholar 

  • Schmeck, H.M., Jr. 1990. Skill and wisdom, as well as the “bottom line,” must guide biotech’s practitioners.GEN10(1):4.

    Google Scholar 

  • Seiken, J. 1992. A reviewer’s eye view of evaluation processes at NIH, NSF.The ScientistMarch 2, p. 19.

    Google Scholar 

  • Shamel, R.E. Biotechnology megatrends: Lessons from the past, visions of the future. in: From the Bench to the Street.(Ed., R.D. Ono) Butterworth, Stoneham, MA, 1991.

    Google Scholar 

  • Slutsker, G. 1991. Pedigree stocks.ForbesJanuary 23, p. 98.

    Google Scholar 

  • Spalding, B.J. 1993. RhĂ´ne-Poulenc buys 37% of Applied Immune.Bio/Technology11:866–867.

    Article  Google Scholar 

  • The review of grant applications that involve especially suitable animal models.NIH Peer Review NotesDivision of Research Grants, NIH, Westwood Building, Bethesda, MD 20892, June, 1991, p. 7.

    Google Scholar 

  • Veggeberg, S. 1993. Despite chill winds on Wall Street, investors continue to place bets on fledgling biotechnology companies.The ScientistApril 5, p. 1.

    Google Scholar 

  • Ward, M. 1994. European alliances should double by 2000.Bio/Technology12(4):345.

    Article  Google Scholar 

  • Wong, J.F. 1993. Investors in biotechnology find themselves in a state of septic shock.GEN13(7):22–23.

    Google Scholar 

  • Yanchinski, S. 1993. In Canada venture capital begins to play a greater role in biotechnology.GEN13(6):3.

    Google Scholar 

  • The ACS Style Guide: AManual forAuthorsand Editor. (Ed., J.S. Dodd) American Chemical Society, Washington, DC, 1986.

    Google Scholar 

Books

  • Anatomy of a Business Plan.by L. Pinson and J. Jinnett. Out of Your Mind…And Into The Marketplace, Fullerton, CA, 1989.

    Google Scholar 

  • The Art of Scientific Writing.by H.F. Ebel, C. Bliefert, and W.R. Russey. VCH Publishers, New York, 1987.

    Google Scholar 

  • The Department of Defense FY 1991 Small Business Innovation Research (SBIR) Program.Solicitation 91.1, US Department of Defense, SBIR Program Office, Washington, DC 20301.

    Google Scholar 

  • The GEN Guide to Venture Capital Companies with Interests in Biotechnology. in: 1991Genetic Engineering News Guide to Biotechnology Companies.Mary Ann Liebert Inc., New York, 1991.

    Google Scholar 

  • Going Public.by M.M. Malone. Edward Burlingame/ Harper Collins, New York, 1991.

    Google Scholar 

  • Guide for the Care and Use of Laboratory Animals.DHEW No. (NIH) 78–23 (revised 1985 and succeeding editions thereof).

    Google Scholar 

  • The “How To” Grants Manual.by D.G. Bauer. American Council on Education/Macmillan, New York, 1984.

    Google Scholar 

  • The Insider’s Guide to Small Business Resources.by D.E. Gumpert and J.A. Timmons. Doubleday, Garden City, New York, 1982.

    Google Scholar 

  • Omnibus Solicitation of the Public Health Service for Small Business Innovation Research (SBIR) Grant and Cooperative Agreement Applications.Department of Health and Human Services, PHS 92–2.

    Google Scholar 

  • Pratt’s Guide to Venture Capital Sources (1991 ed.). Venture Economics Inc., Needham, MA, 1991.

    Google Scholar 

  • The Role of Animals in Biomedical Research.(Ed., J.A. Sechzer) Ann. NY Acad. Sci., vol. 406, The New York Academy of Sciences, New York, 1983.

    Google Scholar 

  • Small Business Innovation Research (SBIR) Program. Phase II Grant Cooperative Agreement Application.Department of Health and Human Services, OMB No. 0925–0195.

    Google Scholar 

  • Small Business Innovation Research (SBIR) Program Solicitation.National Science Foundation, Washington, DC 20550.

    Google Scholar 

  • Solicitation of the Public Health Service and the Health Care Financing Administration for Small Business Innovation Research (SBIR) Contract Proposals.Department of Health and Human Services, PHS/ HFCA 91–1.

    Google Scholar 

  • The Start Up Guide.by D.H. Bangs Jr. Upstart Publishing Co., Dover, NH, 1989.

    Google Scholar 

  • Writing a Successful Grant Application.(2nd ed.) by L. Reil-Lehrer. Jones and Bartlett, Boston, MA, 1989.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Instruments Inc., Norwood, Massachusetts, USA

    Michael G. Pappas PhD

Authors
  1. Michael G. Pappas PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer Science+Business Media New York

About this chapter

Cite this chapter

Pappas, M.G. (1994). Biotechnology Funding. In: The Biotech Business Handbook. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-4612-0293-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-0293-6_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-7139-7

  • Online ISBN: 978-1-4612-0293-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation